U.S. Markets closed

Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Joanne T. Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years of pharmaceutical development and operations experience and is currently the Executive Vice President, Global Pharmaceutical Development and Operations at Celgene. She has joined the Board as Michael Ross, co-Chairman, steps down from Catabasis’ Board of Directors.

“Joanne brings deep knowledge of pharmaceutical development and operations to Catabasis, and we are excited to have her join our board of directors,” said Ken Bate, Chairman of Catabasis’ Board of Directors. “Her leadership experience and knowledge of rare disease pharmaceutical development is a significant asset to the organization as we continue NDA-enabling activities and begin initial preparations for the potential commercial launch of edasalonexent following the completion of the current Phase 3 trial in Duchenne muscular dystrophy. On behalf of the Board and the executive team at Catabasis, I also want to extend my gratitude to Mike Ross for his tremendous leadership and contributions over the past eight years. He has played a critical role in the development of Catabasis and in support of our mission.”

“I am thrilled to have the opportunity to support Catabasis as the organization prepares to bring forward a potential new therapy that could benefit all affected by Duchenne,” said Dr. Beck. “I see great potential for edasalonexent to change the treatment paradigm for Duchenne, and I am honored to be part of this organization and its relentless commitment to improving the lives of those affected by this devastating disease.”

Dr. Beck currently serves on the Board of Directors of Orchard Therapeutics and the Alliance for Regenerative Medicine. Prior to Celgene, Dr. Beck was at Shire and served as Senior Vice President, Pharmaceutical Development from 2014 to 2016 as well as Vice President, Process Development and Manufacturing Sciences from 2012 to 2014. Dr. Beck holds a Bachelor of Arts from Lewis and Clark College (Portland, OR), a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University (Portland, OR) and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the potential commercial launch of edasalonexent, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005268/en/